2024
Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment
Tannu M, Hess C, Gutierrez J, Lopes R, Swaminathan R, Altin S, Rao S. Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment. Current Cardiology Reports 2024, 26: 505-520. PMID: 38743352, DOI: 10.1007/s11886-024-02063-0.Peer-Reviewed Original ResearchGlobal burdenIncreased riskPolyvascular diseaseIncreased risk of bleedingIncreased risk of adverse outcomesRisk factorsVascular territoriesLow-dose anticoagulationLevels of atherogenic lipoproteinsRisk of adverse outcomesAssociated with increased riskLipid-lowering therapyRisk of bleedingAdverse cardiac eventsType 2 diabetes mellitusHigh-risk subgroupsDose of therapyReview of risk factorsReduce disease progressionPresence of atherosclerosisOptimal timingP2Y12 inhibitorsTreatment intensificationEscalating treatmentIschemic benefit
2022
Statins and statin intensity in peripheral artery disease.
Sagris M, Katsaros I, Giannopoulos S, Rosenberg RD, Altin SE, Rallidis L, Mena-Hurtado C, Armstrong EJ, Kokkinidis DG. Statins and statin intensity in peripheral artery disease. Vasa 2022, 51: 198-211. PMID: 35673949, DOI: 10.1024/0301-1526/a001012.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsPeripheral artery diseaseLow-intensity statinsLoss of patencyStatin useStatin doseIntensity statinsArtery diseaseFirst-line lipid-lowering therapyAdverse cardiovascular eventsAmputation-free survivalHigher statin doseLipid-lowering therapyMyocardial infarction rateRisk of amputationImpact of statinsStatin intensityCardiovascular eventsPAD patientsCardiovascular deathCardiovascular mortalityCause mortalityInfarction rateIschemia patientsStatin treatment